… of Nuplazid in people with dementia. Acadia now plans to work with the FDA to clarify and resolve the issues. … dopamine and worsen movement symptoms and therefore more commonly used in Parkinson's. ( Read more about Nuplazid .) … key. Talk with your loved ones, support group and doctor. Together, there are many things, including both medication and …

… Study Rationale/Hypothesis: The goal of this study is to determine the extent to which inflammatory factors in … or with disease is lacking. Such information is needed to support the use of inflammatory factors in biofluids as … the brain. Data analysis is still in progress and once completed will enable us to power a larger study that will …

… Objective/Rationale:              Alpha Galactosidase A (alpha-Gal A) is an enzyme that is ordinarily … responsible for lipid recycling in cells. Researchers have shown how pre-clinical models that lack alpha-Gal A have … disease brain if alpha-Gal A levels or function are compromised. Relevance to Diagnosis/Treatment of Parkinson’s …

… Today The Michael J. Fox Foundation (MJFF) announced a challenge asking data scientists and computational analysts to work with researchers to answer … and testing; answers to these questions would help us target and treat this disease better and faster.” The challenge …

… Yesterday, we reported positive clinical study results into a symptomatic treatment for Parkinson’s disease from … results focused on adenosine were announced from another company – the British-based Vernalis.  According to … drug targeting adenosine in the third phase of clinical testing . Nate Herpich …

… Objective/Rationale: The biotech company nLife Therapeutics has designed a molecule (NLF-PD-1233) to target specific neurons in the brain to reduce expression of …